- Jamie Balarashta - Study Director, Jeffery Trolingera - Principal Investigator
- Aerosol Research and Engineering Laboratories, Kansas
- Full Report
To evaluate the efficacy of the Defend 1050 at reducing aerosolized MS2 bacteriophage, a surrogate for SARS-CoV-2, the disease causing COVID-19.
MS2 bacteriophage was aerosolized into a 16m3, sealed environmental bioaerosol chamber containing the Defend 1050.
AGI impingers were used to sample the chamber bioaerosol concentrations. All impinger samples were serially diluted, plated and enumerated in triplicate to yield viable bioaerosol concentration at each sampling point and time. Samples were taken at 0, 15 and 30 minutes in order to quantify the reduction speed and capabilities of the Defend 1050.
Chamber control trial data was subtracted from the Defend 1050 trial data to yield net LOG reduction in the chamber for the bioaerosol challenges.
Summary of Results
The Defend 1050 was shown to reduce MS2 bacteriophage by 99.99% in 15 minutes.
The Defend 1050 showed a high net log reduction in a relatively short amount of time with average log reduction values ranging from 4.14 net Log in 15 minutes to 4.59 net log reduction in 30 minutes.
A net log reduction over 4.0 in 15 minutes indicates the speed and efficiency of this device against the MS2 bacteriophage.